Program Type: ICER

Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity

Mar 2023 | Policy Paper

ICER has received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.  As part of this project ICER will convene […]

Fair Access: Coverage Policies in 2022

Jan 2023 | Policy Paper

While many key elements of fair access were not able to be assessed, the analysis found that major payer coverage policies for 19 drugs demonstrated high concordance with many fair access criteria related to cost sharing, clinical eligibility, step therapy, and provider restrictions.  During ICER’s assessment, five payers revised policies for 11 drugs in ways […]

Evaluating Reforms to Orphan Drug Development, Pricing, and Coverage

Apr 2022 | Policy Paper

This White Paper examines the potential risks and advantages of reforms to current policies related to orphan drug development, pricing, and coverage. The White Paper does not advocate for specific policy proposals. Instead, it analyzes the potential benefits and risks of reforms that might serve to reshape the incentives for orphan drug development in a […]

Unsupported Price Increases Occurring in 2021

Dec 2022 | Policy Paper

The price of many existing drugs, both brand and generic, can increase substantially over time, and questions are frequently raised regarding whether these price increases are justified. State policymakers have been particularly active in seeking measures to address this issue. In 2019, we launched a new line of ICER reports, named Unsupported Price Increase (UPI) reports, […]

Unsupported Price Increases Occurring in 2020 in California

Oct 2022 | Policy Paper

This California Unsupported Price Increase final report is based on drugs identified through SB-17, the California drug price transparency law. ICER found that increases in spending for many drugs under the SB-17 law may be primarily due to increased volume rather than increases in net price. Final Documents ICER’s Chief Medical Officer David Rind, MD […]

Value Assessment and International Reference Pricing

Sep 2021 | Policy Paper

The need to improve drug affordability remains one of the few areas of bipartisan agreementin the US, with polling showing that a majority of both Democrats and Republicans want thefederal government to act to lower prescription drug prices. Policymakers from both partieshave advanced proposals to rein in drug costs, but there is no consensus on […]